Literature DB >> 19756867

Predicting early chemotherapy response with technetium-99m methoxyisobutylisonitrile SPECT/CT in advanced non-small cell lung cancer.

Tzu-I J Yang1, Tjeerd S Aukema, Harm van Tinteren, Sjaak Burgers, Renato Valdés Olmos, Marcel Verheij.   

Abstract

PURPOSE: The purpose of this study is to examine the prognostic value of prechemotherapy technetium-99m methoxyisobutylisonitrile ((99m)Tc-MIBI) uptake with single photon emission computed tomography/computed tomography (SPECT/CT) in relation to tumor size change measured by CT.
METHODS: Eleven patients with stage IIIB/IV non-small cell lung cancer (NSCLC) underwent (99m)Tc-MIBI SPECT/CT within 24 h before starting platinum-containing chemotherapy. Following the Response Evaluation Criteria in Solid Tumors guidelines, 20 lesions from the 11 patients were available for evaluation. Maximum (C (max)) and mean (C (mean)) MIBI counts were calculated for each lesion. One-dimensional (1D; longest diameter) and two-dimensional (2D; area of the largest transverse surface) tumor measurements were assessed by two observers on the diagnostic CT and the response assessment CT after two cycles of chemotherapy.
RESULTS: Bland-Altman analysis demonstrated no clinically significant bias between the observers. A solid correlation was found between (99m)Tc-MIBI C (mean) and change in the longest diameter (1D change) of the target lesion (rho = -0.62) using Spearman's rank correlation test. C (mean) also correlated negatively with change in the area of the largest transverse surface (2D change) of the target lesion (rho = -0.53). Furthermore, a correlation was established between (99m)Tc-MIBI C (max) and 1D change (rho = -0.56) in tumor size as well, though less strongly when compared to its C (mean) counterpart.
CONCLUSIONS: Our series demonstrated solid, negative correlations between prechemotherapy (99m)Tc-MIBI uptake and tumor size change measured by CT for advanced NSCLC, particularly with C (mean) and 1D change.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756867     DOI: 10.1007/s11307-009-0250-z

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  33 in total

Review 1.  Apoptosis-regulating proteins as targets for drug discovery.

Authors:  J C Reed
Journal:  Trends Mol Med       Date:  2001-07       Impact factor: 11.951

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

4.  Comparative study of Tc-99m MIBI and TI-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer.

Authors:  Y Nishiyama; Y Yamamoto; K Satoh; M Ohkawa; K Kameyama; E Hayashi; J Fujita; M Tanabe
Journal:  Clin Nucl Med       Date:  2000-05       Impact factor: 7.794

5.  Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer.

Authors:  L Kostakoglu; P Kiratli; S Ruacan; M Hayran; S Emri; E L Ergün; C F Bekdik
Journal:  J Nucl Med       Date:  1998-02       Impact factor: 10.057

6.  Tc-99m MIBI SPECT in prediction of prognosis in patients with small cell lung cancer.

Authors:  Aysegul Akgun; Gursel Cok; Inanc Karapolat; Tuncay Goksel; Zeynep Burak
Journal:  Ann Nucl Med       Date:  2006-05       Impact factor: 2.668

7.  Technetium-99m-MIBI uptake in small cell lung cancer.

Authors:  H S Bom; Y C Kim; H C Song; J J Min; J Y Kim; K O Park
Journal:  J Nucl Med       Date:  1998-01       Impact factor: 10.057

8.  Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy.

Authors:  L Ceriani; L Giovanella; M Bandera; B Beghe; M Ortelli; G Roncari
Journal:  Nucl Med Commun       Date:  1997-11       Impact factor: 1.690

9.  Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer.

Authors:  Marina Kartachova; Nico van Zandwijk; Sjaak Burgers; Harm van Tinteren; Marcel Verheij; Renato Alfredo Valdés Olmos
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

10.  99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy.

Authors:  Frank J P Hoebers; Marina Kartachova; Josien de Bois; Michiel W M van den Brekel; Harm van Tinteren; Marcel van Herk; Coen R N Rasch; Renato A Valdés Olmos; Marcel Verheij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-10       Impact factor: 9.236

View more
  1 in total

1.  99mTc-3PRGD2 SPECT Predicts the Outcome of Endostar and Cisplatin Therapy in Xenograft Animals.

Authors:  Wei Sun; Guifu He; Mingming Zhang; Yi Zhao; Hongmei Yu; Yi Li; Wei Wu; Tiefeng Ji
Journal:  Dose Response       Date:  2019-10-20       Impact factor: 2.658

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.